Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 3Genitourinary 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 17Specimen Handling 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Paclitaxel 7Biopsy 7Nivolumab 6atezolizumab 5Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Practice Guidelines as Topic 4Pemetrexed 4Oxaliplatin 4Cyclophosphamide 4Carboplatin 4osimertinib 3niraparib 3durvalumab 3cemiplimab 3avelumab 3Radiotherapy 3Radiation 3Leucovorin 3Irinotecan 3Ipilimumab 3Interviews as Topic 3Fluorouracil 3trastuzumab deruxtecan 2trametinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Tiragolumab × Tumor-Agnostic × Clear all
NCT06754501 2026-02-18

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
4 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡